Cargando…
Gerosuppression by pan-mTOR inhibitors
Rapamycin slows organismal aging and delays age-related diseases, extending lifespan in numerous species. In cells, rapamycin and other rapalogs such as everolimus suppress geroconversion from quiescence to senescence. Rapamycin inhibits some, but not all, activities of mTOR. Recently we and others...
Autores principales: | Leontieva, Olga V., Blagosklonny, Mikhail V. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5270685/ https://www.ncbi.nlm.nih.gov/pubmed/28077803 http://dx.doi.org/10.18632/aging.101155 |
Ejemplares similares
-
Gerosuppression in confluent cells
por: Leontieva, Olga V., et al.
Publicado: (2014) -
As expected, based on rapamycin-like p53-mediated gerosuppression, mTOR inhibition acts as a checkpoint in p53-mediated tumor suppression
por: Blagosklonny, Mikhail V.
Publicado: (2022) -
DNA damaging agents and p53 do not cause senescence in quiescent cells, while consecutive re-activation of mTOR is associated with conversion to senescence
por: Leontieva, Olga V., et al.
Publicado: (2010) -
Mechanistic or mammalian target of rapamycin (mTOR) may determine robustness in young male mice at the cost of accelerated aging
por: Leontieva, Olga V., et al.
Publicado: (2012) -
Tumor suppression by p53 without apoptosis and senescence: conundrum or rapalog-like gerosuppression?
por: Blagosklonny, Mikhail V.
Publicado: (2012)